Sign Up to like & get
recommendations!
0
Published in 2021 at "Expert Opinion on Emerging Drugs"
DOI: 10.1080/14728214.2021.1898588
Abstract: ABSTRACT Introduction The large percentage of adults with major depressive disorder (MDD) insufficiently responding and/or tolerating conventional monoamine-based antidepressants invites the need for mechanistically novel treatments. Convergent evidence implicates glutamatergic signaling as a potential therapeutic…
read more here.
Keywords:
depression;
mdd;
treatment;
dxm bupropion ... See more keywords